TELL enables patients and clinicians to make timely decisions about brain health through automated speech analysis, a cutting-edge, non-invasive method to identify, discriminate, and monitor neurodegenerative diseases. These disorders, including Alzheimer's and Parkinson's disease, affect 100 million people worldwide and cost over one trillion dollars annually in Latin America alone, creating an urgent need for inexpensive, flexible, and consistent markers that favor early detection. Current diagnostic tools are slow, expensive, subjective, and often inaccessible to those in non-urban areas. This leads to expensive R&D, delayed treatments, and underserved patients. TELL offers a solution with automated, affordable, and scalable speech and language tests that use artificial intelligence to capture reliable markers of brain anomalies.

Toolkit to Examine Lifelike Language (TELL)

Toolkit to Examine Lifelike Language (TELL)